Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Stanbery

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|March 24, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncologySusan Morand, Lauren Rager, Daniel Craig, et al.
Future Science OA|March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathyFabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Gynecologic Oncology|November 15, 2024
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancerManoj Sonavane, Jenna Hedlich-Dwyer, Valeria L Dal Zotto, et al.
Vaccines|August 28, 2021
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian CancerRodney P Rocconi, Laura Stanbery, Luciana Madeira da Silva, et al.
Gynecologic Oncology Reports|June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]Jonathan Oh, Minal Barve, Neil Senzer, et al.
Journal of Cancer|January 4, 2021
Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsVinaya Gogineni, Susan Morand, Hannah Staats, et al.
Translational Oncology|August 7, 2010
High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell CarcinomaLaura Stanbery, Nisha J D'Silva, Julia S Lee, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Scientific Reports|July 5, 2024
3D engineered scaffold for large-scale Vigil immunotherapy productionFabienne Kerneis, Ernest Bognar, Laura Stanbery, et al.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|March 24, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncologySusan Morand, Lauren Rager, Daniel Craig, et al.
Future Science OA|March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathyFabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Gynecologic Oncology|November 15, 2024
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancerManoj Sonavane, Jenna Hedlich-Dwyer, Valeria L Dal Zotto, et al.
Vaccines|August 28, 2021
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian CancerRodney P Rocconi, Laura Stanbery, Luciana Madeira da Silva, et al.
Gynecologic Oncology Reports|June 7, 2021
Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648]Jonathan Oh, Minal Barve, Neil Senzer, et al.
Journal of Cancer|January 4, 2021
Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsVinaya Gogineni, Susan Morand, Hannah Staats, et al.
Translational Oncology|August 7, 2010
High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell CarcinomaLaura Stanbery, Nisha J D'Silva, Julia S Lee, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Scientific Reports|July 5, 2024
3D engineered scaffold for large-scale Vigil immunotherapy productionFabienne Kerneis, Ernest Bognar, Laura Stanbery, et al.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Pageof 5